There were some beneficial effects compared to placebo or antidepressants but tolerability was worse .
Quetiapine was more effective than placebo treatment .
Aripiprazole and quetiapine and partly also olanzapine and risperidone augmentation showed beneficial effects compared to placebo .
Some evidence indicated beneficial effects of low-dose amisulpride for dysthymic people .
Most SGAs showed worse tolerability
BACKGROUND Major depressive disorder ( MDD ) is a common condition with a lifetime prevalence of 15 % to 18 % , which leads to considerable suffering and disability .
Some antipsychotics have been reported to induce remission in major depression , when added to an antidepressant .
OBJECTIVES To evaluate the effects of second-generation antipsychotic ( SGA ) drugs ( alone or augmentation ) compared with placebo or antidepressants for people with MDD or dysthymia .
Efficacy and tolerability of extended release quetiapine fumarate monotherapy as maintenance treatment of major depressive disorder: a randomized, placebo-controlled trial.
BACKGROUND PRIMARY OBJECTIVE evaluate the efficacy ( time to recurrence of depressive symptoms ) of once daily extended release quetiapine fumarate ( quetiapine XR ) as maintenance monotherapy treatment to prevent relapse for major depressive disorder ( MDD ) . METHODS Time-to-event ( maximum 52 weeks ) , double-blind , multicenter , r and omized withdrawal , placebo-controlled study of quetiapine XR ( 50 - 300 mg/day ) comprising four treatment phases : enrollment ( up to 28 days ) , open-label run-in ( 4 - 8 weeks ) , open-label stabilization ( 12 - 18 weeks ) , and r and omization ( up to 52 weeks ) . Seven hundred and seventy-six patients stabilized on quetiapine XR were eligible for r and omization ( Montgomery-Åsberg Depression Rating Scale [ MADRS ] score ≤12 and Clinical Global Impression-Severity of Illness [ CGI-S ] score ≤3 ) ; 391 received quetiapine XR and 385 received placebo ( same dose as last open-label visit ) . Primary endpoint : time to recurrence of depressive event from r and omization . Secondary outcomes included changes from r and omization in MADRS total , CGI-S , Pittsburgh Sleep Quality Index ( PSQI ) global , and Hamilton Anxiety Rating Scale ( HAM-A ) total scores . Adverse events were recorded throughout . RESULTS Risk of recurrence of depressive event was significantly ( P<.001 ) reduced by 66 % ( HR=.34 ; 95 % CI : .25 , .46 ) in patients r and omized to continue with quetiapine XR versus patients r and omized to switch to placebo . During the r and omized phase , quetiapine XR maintained improvements in secondary outcomes ( P<.001 for all ) : MADRS ( 0.15 versus 2.03 ) , CGI-S ( -0.03 versus 0.23 ) ; PSQI global ( 0.06 versus 1.35 ) , and HAM-A total score ( 0.20 versus 1.58 ) , respectively . The most common AEs ( > 10 % any group ) during the r and omized period were headache and insomnia . CONCLUSIONS Quetiapine XR maintenance therapy significantly reduced the risk of a depressive event in patients with MDD stabilized on quetiapine XR , with a safety and tolerability profile consistent with the known profile of quetiapine
There were some beneficial effects compared to placebo or antidepressants but tolerability was worse .
Quetiapine was more effective than placebo treatment .
Aripiprazole and quetiapine and partly also olanzapine and risperidone augmentation showed beneficial effects compared to placebo .
Some evidence indicated beneficial effects of low-dose amisulpride for dysthymic people .
Most SGAs showed worse tolerability
BACKGROUND Major depressive disorder ( MDD ) is a common condition with a lifetime prevalence of 15 % to 18 % , which leads to considerable suffering and disability .
Some antipsychotics have been reported to induce remission in major depression , when added to an antidepressant .
OBJECTIVES To evaluate the effects of second-generation antipsychotic ( SGA ) drugs ( alone or augmentation ) compared with placebo or antidepressants for people with MDD or dysthymia .